嗜酸性粒细胞性与非嗜酸性粒细胞性慢阻肺急性加重后心血管事件风险比较
基于TriNetX网络的回顾性队列研究纳入2022至2024年≥40岁慢阻肺急性加重患者143,517例,其中嗜酸性粒细胞性33,761例。
要点
- 嗜酸性粒细胞性慢阻肺急性加重患者1年MACE风险显著低于非嗜酸性粒细胞性患者。
- 嗜酸性粒细胞性急性加重也与心力衰竭、急性心肌梗死、卒中、心律失常及全因死亡风险降低相关。
- 急性加重时血嗜酸性粒细胞计数或可用于分层长期心血管风险。
核心结论
- 嗜酸性粒细胞性慢阻肺急性加重与非嗜酸性粒细胞性相比,1年主要不良心血管事件风险显著降低。
主要发现
- 嗜酸性粒细胞性急性加重还与心力衰竭、急性心肌梗死、卒中、心律失常及全因死亡风险降低相关。
- 敏感性分析包括替代嗜酸性粒细胞阈值和landmark时间窗,结果一致。
关键数值与推荐
- 嗜酸性粒细胞性急性加重定义为事件前3天至后1天内血嗜酸性粒细胞计数≥300/μL。
- 主要结局为1年MACE风险,包括心力衰竭、左心室射血分数降低、急性心肌梗死、脑梗死、心脏骤停和心律失常。
临床怎么用
- 急性加重时血嗜酸性粒细胞计数可作为生物标志物,用于分层慢阻肺患者长期心血管风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute exacerbation of COPD (AE-COPD) is associated with increased cardiovascular risk, but whether this risk differs between eosinophilic and non-eosinophilic AE-COPD remains unclear. RESEARCH QUESTION: Is eosinophilic AE-COPD associated with a lower risk of major adverse cardiovascular events (MACEs)? STUDY DESIGN AND METHODS: This retrospective cohort study was conducted by using the TriNetX Analytics Network. Patients aged ≥ 40 years with AE-COPD between January 1, 2022, and December 31, 2024, were included. Eosinophilic AE-COPD was defined as a blood eosinophil count ≥ 300/μL within the window of 3 days before to 1 day following the event. The primary outcome was the 1-year risk of MACEs (heart failure, reduced left ventricular ejection fraction, acute myocardial infarction, cerebral infarction, cardiac arrest, and arrhythmia). Propensity score matching (1:1) was performed, and Cox proportional hazards models and Kaplan-Meier analyses were used. Sensitivity analyses included negative/positive control outcomes, alternative eosinophil cutoff definitions, and landmark analyses. RESULTS: A total of 143,517 patients were included (33,761 eosinophilic and 109,756 non-eosinophilic AE-COPD). After matching, 33,756 patients were retained in each group. During the 1-year follow-up, non-eosinophilic AE-COPD was associated with a higher risk of MACEs compared with eosinophilic AE-COPD (5,967 vs 5,160 events; hazard ratio, 1.22; 95% CI, 1.17-1.26; P < .001). Kaplan-Meier analysis confirmed higher MACE-free survival in patients with eosinophilic AE-COPD (log-rank test, P < .001). Eosinophilic AE-COPD was also associated with reduced risks of heart failure, acute myocardial infarction, stroke, arrhythmia, and all-cause mortality. Findings were consistent across sensitivity analyses, including alternative eosinophil thresholds and landmark time windows. INTERPRETATION: Our results show eosinophilic AE-COPD was associated with a significantly lower risk of MACE compared with non-eosinophilic AE-COPD. Blood eosinophil count at the time of exacerbation may serve as a valuable biomarker for stratifying not only pulmonary outcomes but also long-term cardiovascular risk in COPD.
引用
- Lin, Zhong, Chou, et al. Eosinophilic vs Non-Eosinophilic Acute Exacerbations of COPD and Subsequent Cardiovascular Event. Chest. 2026. PMID: 41932679. doi:10.1016/j.chest.2026.03.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。